| Aug 2 |
Down -39.63% in 4 Weeks, Here's Why You Should You Buy the Dip in PepGen (PEPG)
|
| Jul 31 |
PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments
|
| Jul 31 |
PepGen reports positive data from Phase II Duchenne muscular dystrophy trial
|
| Jul 30 |
PepGen stock tumbles 25% following release of DMD drug data
|
| Jul 30 |
PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy
|
| Jul 17 |
Recent Price Trend in PepGen (PEPG) is Your Friend, Here's Why
|
| Jul 2 |
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications
|
| Jun 28 |
PepGen files for $250M mixed securities shelf
|
| Jun 11 |
PepGen gets new medical head
|
| Jun 11 |
PepGen Announces Executive Team Promotions
|
